Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Jeremy D. Kratz"'
Autor:
Rebecca A. DeStefanis, Jeremy D. Kratz, Autumn M. Olson, Aishwarya Sunil, Alyssa K. DeZeeuw, Amani A. Gillette, Gioia C. Sha, Katherine A. Johnson, Cheri A. Pasch, Linda Clipson, Melissa C. Skala, Dustin A. Deming
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-14 (2022)
Abstract Representative models are needed to screen new therapies for patients with cancer. Cancer organoids are a leap forward as a culture model that faithfully represents the disease. Mouse-derived cancer organoids (MDCOs) are becoming increasingl
Externí odkaz:
https://doaj.org/article/0850400bc08146908046414b05f6fcca
Publikováno v:
Clinical Case Reports, Vol 8, Iss 12, Pp 3302-3309 (2020)
Abstract B‐cell lymphomas with atypical presentation or immunophenotype pose diagnostic challenges. Conventional ancillary tests (cytogenetics, FISH) can help, but have technical limitations. New technologies such as mate‐pair sequencing (MPSeq)
Externí odkaz:
https://doaj.org/article/d79b427b13454517a03574cfa861e8df
Autor:
Md Shahadat Hossan, Ethan Samuel Lin, Eleanor Riedl, Austin Stram, Eric Mehlhaff, Luke Koeppel, Jamie Warner, Inem Uko, Lori Mankowski Gettle, Sam Lubner, Stephanie M. McGregor, Wei Zhang, William Murphy, Jeremy D. Kratz
Publikováno v:
Bioengineering, Vol 10, Iss 1, p 91 (2023)
Pancreatic and ampullary cancers remain highly morbid diseases for which accurate clinical predictions are needed for precise therapeutic predictions. Patient-derived cancer organoids have been widely adopted; however, prior work has focused on well-
Externí odkaz:
https://doaj.org/article/b5633220274c4edbb458f908775e1f79
Publikováno v:
Journal of Clinical Oncology. 40:2751-2762
Immunotherapy (IO) agents have led to significant improvements in patient outcomes across many tumor types. There have been great efforts to introduce immune checkpoint inhibitors into the treatment paradigm of esophagogastric cancers as well. A numb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34760a2f4458c47ef726dcae06aea99c
https://doi.org/10.1200/jco.21.02500
https://doi.org/10.1200/jco.21.02500
Autor:
Manabu Nukaya, Crystal Cafferty, Katerina Zahed, Isabelle Yun, David P. Al-Adra, Noor A. Kazim, Alaa R. Farghli, Marina Chan, Jeremy D. Kratz, Mark E. Berres, Andrew Yen, Taranjit S. Gujral, Praveen Sethupathy, Christopher A. Bradfield, Sean M. Ronnekleiv-Kelly
SummaryFibrolamellar carcinoma (FLC) is a rare and lethal cancer that afflicts young individuals. The tumor arises in the background of a healthy liver, and patients typically present with advanced cancer at the time of diagnosis. Unfortunately, for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aeb5ffb3ddc0a2d4b28513f6b5d7c722
https://doi.org/10.1101/2023.04.22.537934
https://doi.org/10.1101/2023.04.22.537934
Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
Autor:
Dustin A. Deming, Melissa C. Skala, Michael A. Newton, Kristina A. Matkowskyj, Paraic A. Kenny, Benjamin M. Parsons, Kayla K. Lemmon, Mark E. Burkard, Linda Clipson, Rebecca A. DeStefanis, Gioia Chengcheng Sha, Demetra P. Korkos, Mitchell G. Depke, Dana R. Van De Hey, Alexander E. Yueh, Tyler M. Foley, Cheri A. Pasch, Jeremy D. Kratz, Peter F. Favreau, Susan N. Payne, Stephanie L. Fricke
Supplementary Figure S1 presents the viability of SW48 and SW48PK cells after treatment with BEZ235 and TAK-228 at the 100-400nM concentrations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3797d51c82d44138bbd5766b7be6a207
https://doi.org/10.1158/1535-7163.22507717.v1
https://doi.org/10.1158/1535-7163.22507717.v1
Autor:
Dustin A. Deming, Melissa C. Skala, Michael A. Newton, Kristina A. Matkowskyj, Paraic A. Kenny, Benjamin M. Parsons, Kayla K. Lemmon, Mark E. Burkard, Linda Clipson, Rebecca A. DeStefanis, Gioia Chengcheng Sha, Demetra P. Korkos, Mitchell G. Depke, Dana R. Van De Hey, Alexander E. Yueh, Tyler M. Foley, Cheri A. Pasch, Jeremy D. Kratz, Peter F. Favreau, Susan N. Payne, Stephanie L. Fricke
PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only limited data to support
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61eef4938e53e1487200610ced459f4f
https://doi.org/10.1158/1535-7163.c.6538765.v1
https://doi.org/10.1158/1535-7163.c.6538765.v1
Publikováno v:
Expert Review of Precision Medicine and Drug Development. 7:121-130
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dccb7cdf41b82f005d7fc6adcdba8ca1
https://doi.org/10.1080/23808993.2022.2106852
https://doi.org/10.1080/23808993.2022.2106852
Autor:
Ethan Samuel Lin, Md Shahadat Hossan, Austin Stram, Eleanor E. Riedl, Luke J. Koeppel, Jaimie M. Warner, Jeremy D. Kratz
Publikováno v:
Cancer Research. 83:5327-5327
Background: Therapeutic screening Pancreatic Ductal Adenocarcinoma (PDAC) relies on well-level assessment for high throughput response evaluation. Patient-derived cancer organoids (PCOs) model subclonal populations, however the significance of resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22534ec74a3010339fa3c00f50758eb4
https://doi.org/10.1158/1538-7445.am2023-5327
https://doi.org/10.1158/1538-7445.am2023-5327
Publikováno v:
Annu Rev Biomed Eng
Patient-derived cancer organoids (PDCOs) are organotypic 3D cultures grown from patient tumor samples. PDCOs provide an exciting opportunity to study drug response and heterogeneity within and between patients. This research can guide new drug develo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53602017c3116b5cf9f3fd79f74d45a8
https://europepmc.org/articles/PMC9177801/
https://europepmc.org/articles/PMC9177801/